MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00392-025-02691-8

Медицинская библиотека · Clinical research in cardiology : official journal of the German Cardiac Society · 2025

CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis.

Zlibut Alexandru, Bietenbeck Michael, Akyol Nuriye, Vehof Volker, Bouras Redouane, Isgandarova Khuraman, Meier Claudia, Theofanidou Maria, Stalling Philipp, Yilmaz Ali

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES AND

BACKGROUND

The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12 months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).

METHODS

Patients with confirmed ATTR-CM (N = 56) were divided into two groups: in the larger group A (N = 39; 95% male), treatment with tafamidis 61 mg once daily was initiated after the first CMR study, whereas group B (N = 17; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27 ± 6 months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.

RESULTS

Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (p = 0.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48% p < 0.001 vs 56% to 46%, p < 0.001; -7.4 to -5.3, p < 0.001 vs -8.8 to -4.8, p < 0.001). However, the tafamidis-naïve group B experienced a substantially higher impairment of both parameters when compared to group A (∆p = 0.008 and ∆p = 0.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (from 18.2 mm to 21.1 mm at follow-up, p < 0.001) compared to the tafamidis-treated group A (from 18.5 mm to 19.2 mm, p = 0.012; ∆p < 0.001). Both global native T1 and global ECV values were significantly elevated in both groups-at baseline and at follow-up-with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-naïve group B compared to the tafamidis-treated group A (group A: 51% to 57%, p < 0.001; group B: 50% to 67%, p < 0.001; ∆p < 0.001).

CONCLUSION

Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2 years. However, the "extent of worsening" is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients.

Для цитирования: Zlibut Alexandru, Bietenbeck Michael, Akyol Nuriye, Vehof Volker, Bouras Redouane, Isgandarova Khuraman, Meier Claudia, Theofanidou Maria, Stalling Philipp, Yilmaz Ali. CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis.. Clinical research in cardiology : official journal of the German Cardiac Society. 2025. DOI: 10.1007/s00392-025-02691-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.